Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Olaparib vs Enzalutamide or Abiraterone in HRR-mutated mCRPC After Prior New Hormonal Agent
jRCT2080223497Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2017
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of olaparib in prostate cancer (PCa) (2 arms), sponsored by AstraZeneca. Started Mar 2017; status: completed.
02
Drugs
olaparib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2080223497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223497.